Press coverage about Concert Pharmaceuticals (NASDAQ:CNCE) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.8501433085878 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several equities analysts have recently weighed in on the stock. Mizuho restated a “buy” rating and set a $27.00 price objective on shares of Concert Pharmaceuticals in a research report on Tuesday. ValuEngine upgraded shares of Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, April 3rd. TheStreet lowered shares of Concert Pharmaceuticals from a “b-” rating to a “c” rating in a research report on Thursday, March 29th. BidaskClub lowered shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, March 28th. Finally, Zacks Investment Research upgraded shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 8th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $25.67.
Shares of NASDAQ:CNCE traded up $0.81 during trading hours on Thursday, hitting $20.20. 336,020 shares of the company’s stock traded hands, compared to its average volume of 401,938. Concert Pharmaceuticals has a 52 week low of $11.88 and a 52 week high of $30.71. The firm has a market cap of $437.25, a price-to-earnings ratio of 4.95 and a beta of 1.02.
Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08). Concert Pharmaceuticals had a net margin of 66.47% and a negative return on equity of 36.25%. The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $8.11 million. equities analysts forecast that Concert Pharmaceuticals will post -2.35 earnings per share for the current year.
In other Concert Pharmaceuticals news, Director Richard Aldrich sold 31,236 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $19.14, for a total transaction of $597,857.04. Following the completion of the sale, the director now directly owns 286,975 shares of the company’s stock, valued at $5,492,701.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 136,236 shares of company stock valued at $2,688,563 over the last ninety days. Insiders own 10.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/12/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-concert-pharmaceuticals-cnce-stock-price.html.
Concert Pharmaceuticals Company Profile
Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.